CA2738930C - Procede d'inhibition d'une activite procoagulante induite par des biomateriaux utilisant des inhibiteurs de complements - Google Patents

Procede d'inhibition d'une activite procoagulante induite par des biomateriaux utilisant des inhibiteurs de complements Download PDF

Info

Publication number
CA2738930C
CA2738930C CA2738930A CA2738930A CA2738930C CA 2738930 C CA2738930 C CA 2738930C CA 2738930 A CA2738930 A CA 2738930A CA 2738930 A CA2738930 A CA 2738930A CA 2738930 C CA2738930 C CA 2738930C
Authority
CA
Canada
Prior art keywords
inhibitor
blood
biomaterial
complement
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2738930A
Other languages
English (en)
Other versions
CA2738930A1 (fr
Inventor
John D. Lambris
Konstantinos Ritis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of CA2738930A1 publication Critical patent/CA2738930A1/fr
Application granted granted Critical
Publication of CA2738930C publication Critical patent/CA2738930C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • External Artificial Organs (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés destinés à réduire ou à éliminer une activité procoagulante induite par des biomatériaux dans le sang soumis à un traitement extracorporel qui expose le sang au biomatériau. Les procédés comprennent le traitement du sang, ou du biomatériau extracorporel, ou des deux, par un inhibiteur du complément afin dinhiber la formation de facteurs tissulaires induits par les C5a/C5aR dans le sang.
CA2738930A 2008-09-30 2009-09-29 Procede d'inhibition d'une activite procoagulante induite par des biomateriaux utilisant des inhibiteurs de complements Active CA2738930C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10145308P 2008-09-30 2008-09-30
US61/101,453 2008-09-30
PCT/US2009/058745 WO2010039690A1 (fr) 2008-09-30 2009-09-29 Procédé d’inhibition d’une activité procoagulante induite par des biomatériaux utilisant des inhibiteurs de compléments

Publications (2)

Publication Number Publication Date
CA2738930A1 CA2738930A1 (fr) 2010-04-08
CA2738930C true CA2738930C (fr) 2021-08-17

Family

ID=42073834

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2738930A Active CA2738930C (fr) 2008-09-30 2009-09-29 Procede d'inhibition d'une activite procoagulante induite par des biomateriaux utilisant des inhibiteurs de complements

Country Status (5)

Country Link
US (1) US8445190B2 (fr)
EP (1) EP2340028B1 (fr)
AU (1) AU2009298684B2 (fr)
CA (1) CA2738930C (fr)
WO (1) WO2010039690A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3028716T (pt) 2006-10-10 2020-11-23 Regenesance B V Inibição do complemento para regeneração nervosa melhorada
CA2738930C (fr) * 2008-09-30 2021-08-17 The Trustees Of The University Of Pennsylvania Procede d'inhibition d'une activite procoagulante induite par des biomateriaux utilisant des inhibiteurs de complements
AU2012326976B2 (en) 2011-10-21 2017-08-17 Takeda Pharmaceutical Company Limited Sustained-release preparation
EP2886140A1 (fr) * 2013-12-17 2015-06-24 University of Limerick Appareil pour le traitement extracorporel du sang
US10633434B2 (en) 2016-06-14 2020-04-28 Regeneron Pharmaceuticals, Inc. Anti-C5 antibodies
KR20200098528A (ko) 2017-12-13 2020-08-20 리제너론 파아마슈티컬스, 인크. 항-c5 항체 조합물 및 이의 용도
CN114630836A (zh) * 2019-08-27 2022-06-14 西兰制药第三特殊目的公司 补体抑制素类似物及其医学用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2000505068A (ja) * 1996-03-13 2000-04-25 トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 補体活性化を阻害する新規ペプチド類
AU2006202394A1 (en) * 1997-08-26 2006-06-29 Abgenix, Inc. A process for inhibiting complement activation via the alternative pathway
WO1999013899A1 (fr) 1997-09-17 1999-03-25 Trustees Of The University Of Pennsylvania Peptides et peptidomimetiques inhibant l'activation du complement
AU3066699A (en) * 1998-03-03 1999-09-20 Johns Hopkins University, The Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
WO2001085664A2 (fr) * 2000-05-10 2001-11-15 Princeton University Composes et procedes utilises pour reguler la croissance bacterienne et la pathogenie
AUPR833401A0 (en) 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
AU2002357932A1 (en) 2001-12-18 2003-06-30 Whitehead Institute For Biomedical Research Fusion partner cells and uses thereof
EP2311480B1 (fr) 2002-09-20 2013-06-26 The Trustees of The University of Pennsylvania Analogues de la compstatine dotés d'une activité améliorée
US7959919B2 (en) 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
US7803931B2 (en) * 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
RU2474586C2 (ru) * 2005-11-28 2013-02-10 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Эффективные аналоги компстатина
HUE026001T2 (en) * 2007-02-05 2016-04-28 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
US8192742B2 (en) * 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
US20110160636A1 (en) * 2008-09-10 2011-06-30 Rekha Bansal Device and method for inhibiting complement activation
CA2738930C (fr) * 2008-09-30 2021-08-17 The Trustees Of The University Of Pennsylvania Procede d'inhibition d'une activite procoagulante induite par des biomateriaux utilisant des inhibiteurs de complements

Also Published As

Publication number Publication date
EP2340028B1 (fr) 2018-06-27
AU2009298684B2 (en) 2015-11-19
EP2340028A1 (fr) 2011-07-06
US20110269113A1 (en) 2011-11-03
US8445190B2 (en) 2013-05-21
AU2009298684A1 (en) 2010-04-08
EP2340028A4 (fr) 2013-07-10
WO2010039690A1 (fr) 2010-04-08
CA2738930A1 (fr) 2010-04-08

Similar Documents

Publication Publication Date Title
CA2738930C (fr) Procede d'inhibition d'une activite procoagulante induite par des biomateriaux utilisant des inhibiteurs de complements
Jourde-Chiche et al. Endothelium structure and function in kidney health and disease
Frantzeskaki et al. Immunothrombosis in acute respiratory distress syndrome: cross talks between inflammation and coagulation
JP7397037B2 (ja) Ｍａｓｐ－２依存性補体活性化に関連した状態を治療するための方法
Vassalli et al. The pathogenic role of the coagulation process in rabbit Masugi nephritis
CN107638565B (zh) 用于治疗与masp-2依赖性补体活化相关的状况的方法
US9358266B2 (en) Treatment of sepsis using complement inhibitors
Nymo et al. Cholesterol crystal-induced endothelial cell activation is complement-dependent and mediated by TNF
WO2012166611A2 (fr) Procédés de traitement et de prévention d'une toxicité net dérivée des neutrophiles et d'une thrombose
M Risitano et al. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3
JP6055464B2 (ja) 循環血中の可溶性ウロキナーゼ受容体の低減
TW202402809A (zh) 用於治療和／或預防與造血幹細胞移植有關的移植物抗宿主病和／或瀰漫性肺泡出血和／或靜脈閉塞性病的方法
CN117398458A (zh) 用于治疗与masp-2依赖性补体活化相关的病况的方法
US20210179717A1 (en) Antibodies against mac-1
RU2714112C2 (ru) Терапевтическая APAC-молекула, содержащая гепарин, конъюгированный с белком плазмы крови
JP2009539757A (ja) 血栓溶解活性を有するａｄａｍｔｓ１３含有組成物
US20240156906A1 (en) Anticoagulant proteins and their use for treating diseases associated with the activation of neutrophils
Li et al. Complement as new immunotherapy target: past, present, and future
Mannes Lessons from and for complement therapeutics: Novel mechanistic insights into terminal pathway activation and its linkage to thrombosis
Blatt Role of complement regulatory proteins properdin and factor H in platelet/granulocyte aggregate formation
Hardersen Biocompatibility in low-density lipoprotein apheresis and plasma separation
Ward et al. Complement System
WO2023152291A1 (fr) Méthodes et composition pharmaceutique pour le traitement de troubles thrombotiques
櫻井健太郎 Role for Neutrophil Extracellular Traps (NETs) and Platelet Aggregation in Early Sepsis-induced Hepatic Dysfunction
Asare et al. Complement Blocking Therapeutic Strategies: A Prospective Approach for the Treatment of Cardiovascular Diseases

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140903